Login / Signup

Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.

Renzo GuerriniCatherine ChironDelphine VandameWarren LinleyToby Toward
Published in: Epilepsia open (2024)
This study compared three drugs (stiripentol, fenfluramine, and cannabidiol) used alongside other medications for managing seizures in a severe type of epilepsy called DS. The study found that stiripentol and fenfluramine were similarly effective in reducing seizures and both were more effective than cannabidiol. Stiripentol was the best drug for stopping seizures completely based on the available clinical trial data. All three drugs had similar rates of serious side effects, but stiripentol had a lower chance of being stopped due to side effects. This information can help guide treatment choices for people with DS.
Keyphrases
  • clinical trial
  • temporal lobe epilepsy
  • healthcare
  • emergency department
  • electronic health record
  • open label
  • big data
  • deep learning
  • adverse drug
  • data analysis
  • combination therapy
  • phase iii